M&T Bank Corp Spectrum Pharmaceuticals Inc Transaction History

M&T Bank Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 12, 2019	SELL	$7.03 - $9.7 $111,207 - $153,444	-15,819 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$7.36 - $11.26 $91,543 - $140,051	-12,438 Reduced 44.02%	15,819 $136,000
Q1 2019 May 15, 2019	SELL	$9.08 - $11.84 $114,825 - $149,728	-12,646 Reduced 30.92%	28,257 $302,000
Q4 2018 Feb 01, 2019	BUY	$6.39 - $16.99 $75,101 - $199,683	11,753 Added 40.32%	40,903 $358,000
Q3 2018 Nov 09, 2018	SELL	$16.52 - $24.82 $207,276 - $311,416	-12,547 Reduced 30.09%	29,150 $489,000
Q2 2018 Aug 10, 2018	SELL	$14.31 - $21.75 $70,376 - $106,966	-4,918 Reduced 10.55%	41,697 $874,000
Q1 2018 May 04, 2018	SELL	$16.09 - $23.07 $160 - $230	-10 Reduced 0.02%	46,615 $750,000
Q4 2017 Feb 06, 2018	BUY	$13.36 - $20.73 $18,263 - $28,337	1,367 Added 3.02%	46,625 $883,000
Q3 2017 Nov 13, 2017	BUY	$8.75 - $14.07 $132,203 - $212,583	15,109 Added 50.11%	45,258 $637,000
Q2 2017 Aug 11, 2017	BUY	N/A	30,149	30,149 $225,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.